Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2632430
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: 1 cycle is 28days. Nintedanib (150mg or 200mg) is orally administered twice daily and TAS-102 (35mg/m2) is orally administered twice daily in 1-5days and 8-12 days
Primary outcome(s): 16 weeks progression free survival rate ( 16W PFS rate)
Study Design: Single arm Non-randomized
干预方案：每个治疗周期为28天。尼达尼布（Nintedanib）150mg或200mg每日两次口服给药；TAS-102 35mg/m²于第1~5天及第8~12天每日两次口服给药。
主要研究终点：16周无进展生存率（16W PFS率）
研究设计：单臂非随机试验
创建时间：
2015-08-15
